Current Report Filing (8-k)
11 Juin 2018 - 10:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 7, 2018
Portola Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35935
|
|
20-0216859
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
270 E. Grand Avenue
South San Francisco, California
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650)
246-7300
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(e)
On June 7, 2018, the Company entered into an
agreement with John H. (Jack) Lawrence, M.D., the Companys Senior Vice President and Chief Medical Officer. Following the appointment of a new Chief Executive Officer of the Company (CEO), Dr. Lawrence will become eligible for
increased severance benefits in addition to those already provided under his existing Executive Severance Benefits Agreement (the Severance Agreement) as follows:
If, during the one (1) year period following the Companys hiring of a new CEO (as measured from the first day of employment for the new CEO), his
employment is terminated without Cause, or he resigns for Good Reason, then: (a) his Severance Period for such Covered Termination shall be twelve (12) months (instead of six (6)); and (b) in addition to the severance benefits set
forth in Section 2.1 of the Severance Agreement, the Company will (subject to the terms and conditions set forth in the Severance Agreement) accelerate the vesting of your equity awards such that he will be deemed vested in such shares that
would have vested had he remained employed for one additional year following his last day of employment with the Company. After the new CEO completes one (1) year of employment with the Company, then these terms have no further force or effect,
however he shall remain eligible for the severance benefits set forth in the Severance Agreement under the terms and conditions set forth therein. (All capitalized terms used in this paragraph that are not otherwise defined shall have the meanings
set forth in the Severance Agreement.)
Item 5.03
|
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
|
On June 8, 2018, at
the annual meeting of stockholders of Portola Pharmaceuticals, Inc. (the Company), upon the recommendation of the Companys Board of Directors, the stockholders voted on and approved an amendment to the Companys
Amended and Restated Certificate of Incorporation, as amended, to increase the Companys authorized common stock from 100,000,000 to 150,000,000 shares (the Amendment).
A Certificate of Amendment was filed with the Secretary of State of the State of Delaware to effect the Amendment on June 8, 2018 and was effective as of such
date. A copy of the Certificate of Amendment is attached as Exhibit 3.1 hereto and is incorporated by reference.
Item 5.07
|
Submission of Matters to a Vote of Security Holders
|
On June 8, 2018, at the annual meeting of
stockholders of the Company, the stockholders voted on the three proposals listed below. The proposals are described in detail in the Companys definitive proxy statement for the 2018 annual meeting, filed with the Securities and Exchange
Commission on April 24, 2018 (the Proxy Statement). The results of the matters voted upon at the meeting were:
|
a)
|
Each of the Class II nominees of the Companys Board of Directors were elected to hold office until the Companys 2021 annual meeting of stockholders. The Class II nominees were: Dennis M. Fenton,
Ph.D.; 46,178,061 shares of Common Stock voted for, 783,242 withheld, and 11,579,062 broker
non-votes;
Charles J. Homcy, M.D.; 46,188,918 shares of Common Stock voted for, 772,385 withheld, and 11,579,062
broker
non-votes;
and David C. Stump; 45,449,876 shares of Common Stock voted for, 1,511,427 withheld, and 11,579,062 broker
non-votes.
|
|
b)
|
The stockholders approved an amendment to the Companys Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of common stock from 100,00,000 to 150,000,000
shares: 55,004,417 shares of Common Stock voted for, 2,870,934 against, 257,265 abstaining, and 407,749 broker
non-votes.
|
|
c)
|
The stockholders approved, on a
non-binding,
advisory basis, of the compensation of the Companys named executive officers as disclosed in the Proxy Statement: 45,475,285
shares of Common Stock voted for, 1,239,205 against, 246,813 abstaining, and 11,579,062 broker
non-votes.
|
|
d)
|
The stockholders ratified the selection by the Audit Committee of the Companys Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal
year ending December 31, 2018: 57,524,397 shares of Common Stock voted for, 924,751 against, 91,217 abstaining, and no broker
non-votes.
|
Item 9.01
|
Financial Statements and Exhibits
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Portola Pharmaceuticals, Inc.
|
|
|
|
|
Dated: June 7, 2018
|
|
|
|
By:
|
|
/s/ Mardi C. Dier
|
|
|
|
|
|
|
Mardi C. Dier
|
|
|
|
|
|
|
Interim
Co-President
and Chief Financial Officer
|
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur Portola Pharmaceuticals Inc